Premium
Plasma HMGB ‐1 after the initial dose of epirubicin/docetaxel in cancer
Author(s) -
Arnold Tobias,
Michlmayr Anna,
Baumann Suzann,
Burghuber Christopher,
Pluschnig Ursula,
Bartsch Rupert,
Steger Guenther,
Gnant Michael,
Bergmann Michael,
BachleitnerHofmann Thomas,
Oehler Rudolf
Publication year - 2013
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12043
Subject(s) - epirubicin , docetaxel , medicine , breast cancer , oncology , chemotherapy , pathological , cancer
Background The response of breast cancer patients to neoadjuvant chemotherapy ( NCT ) is highly heterogeneous, and reliable predictive instruments remain to be defined. High‐mobility group box‐1 ( HMGB ‐1) protein is a cell death marker, which is easily detectable in plasma. We hypothesized that the initial dose of NCT with epirubicin/docetaxel induces changes in plasma HMGB ‐1 which could allow for an early prediction of response to therapy. Materials and methods First, we analysed whether epirubicin/docetaxel releases HMGB ‐1 from HCC 1143 breast cancer cells in vitro . Thereafter, plasma HMGB ‐1 levels before and 1–4 days after the first dose of epirubicin/docetaxel‐based NCT were determined in 41 breast cancer patients and correlated with pathological response to treatment. Results Treatment of HCC 1143 cells with epirubicin/docetaxel resulted in a significant HMGB ‐1 release in vitro . In vivo , HMGB ‐1 levels increased significantly only in responders (pathological complete response or partial remission, n = 22) but not in nonresponders (stable or progressive disease, n = 19). Conclusion Our data suggest that early dynamic changes of plasma HMGB 1 could be a promising biomarker to predict the final response to NCT in breast cancer patients.